Search

Your search keyword '"Salmhofer W"' showing total 207 results
Start Over Author "Salmhofer W"
207 results on '"Salmhofer W"'

3. AB1202 SUCCESSFUL LONG-TERM TREATMENT OF SYSTEMIC SCLEROSIS BY HIGH-FREQUENT, LOW-DOSE B CELL DEPLETING THERAPY

Author

Moazedi-Fuerst, F., primary, Lackner, A., additional, Kreuzer, S., additional, Eller, K., additional, Kovacs, G., additional, Flick, H., additional, Balazs, O., additional, Talakic, E., additional, Hermann, J., additional, Venhoff, N., additional, Venhoff, A., additional, Jud, P., additional, Yazdani-Biuki, B., additional, Brodmann, M., additional, Salmhofer, W., additional, Husic, R., additional, Stradner, M., additional, Graninger, W., additional, Thiel, J., additional, and Brezinsek, H. P., additional

Published
2024
Full Text
View/download PDF

5. 57 Mast cells as potential drivers of inflammation in psoriasis

Author

Benezeder, T., primary, Woltsche, J., additional, Bordag, N., additional, Teufelberger, A., additional, Perchthaler, I., additional, Weger, W., additional, Gruber-Wackernagl, A., additional, Salmhofer, W., additional, Painsi, C., additional, Pankratz, K., additional, El-Heliebi, A., additional, Babina, M., additional, Clark, R., additional, and Wolf, P., additional

Published
2023
Full Text
View/download PDF

11. Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis*

Author

Graier, T., primary, Salmhofer, W., additional, Jonak, C., additional, Weger, W., additional, Kölli, C., additional, Gruber, B., additional, Sator, P.G., additional, Prillinger, K., additional, Mlynek, A., additional, Schütz‐Bergmayr, M., additional, Richter, L., additional, Ratzinger, G., additional, Painsi, C., additional, Selhofer, S., additional, Häring, N., additional, Wippel‐Slupetzky, K., additional, Skvara, H., additional, Trattner, H., additional, Tanew, A., additional, Inzinger, M., additional, Tatarski, R., additional, Bangert, C., additional, Ellersdorfer, C., additional, Lichem, R., additional, Gruber‐Wackernagel, A., additional, Hofer, A., additional, Legat, F., additional, Schmiedberger, E., additional, Strohal, R., additional, Lange‐Asschenfeldt, B., additional, Schmuth, M., additional, Vujic, I., additional, Hoetzenecker, W., additional, Trautinger, F., additional, Saxinger, W., additional, Müllegger, R., additional, Quehenberger, F., additional, and Wolf, P., additional

Published
2021
Full Text
View/download PDF

18. Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study

Author

Sampogna, F., Puig, L., Spuls, P., Girolomoni, G., Radtke, M. A., Kirby, B., Brunori, M., Bergmans, P., Smirnov, P., Rundle, J., Lavie, F., Paul, C., Affleck, A., Antoniou, C., Ayala, F., Bakulev, A., Bam, E., Belinchon, I., Bewley, A., Botella, R., Chasapi, V., Chimenti, S., Cianchini, G., de Jong, E., de Kort, W., Duval-Modeste, A. -B., Fernandez Llaca, J. H., Gaastra, M., Ghislain, P. -D., Goujon, C., Griffiths, C., Horev-Yakir, L., Ioannidis, D., Izu, R., Krasagakis, K., Lacour, J-P., Lambert, J., Lopez Estebaranz, J. L., Malara, G., Markham, T., Matz, H., Mcbride, S., Moseng, D., Nikkels, A., Papakonstantis, M., Pavlotsky, F., Pavlovsky, L., Pellacani, G., Peserico, A., Piccirillo, Aniello, Potenza, C., Prignano, F., Puig Sanz, L., Raboobee, N., Rallis, E., Ramon, M., Reguiai, Z., Riedl, E., Ruer, M., Rustad, L., Salmhofer, W., Sanchez-Carazo, J. L., Schmutz, J. -L., Sokolovsky, E., Sotiriadis, D., Tobin, A. -M., Zhukova, O., Ziv, M., Amsterdam Movement Sciences - Restoration and Development, APH - Methodology, APH - Quality of Care, AII - Inflammatory diseases, and Dermatology

Subjects
Adult, Male, medicine.medical_specialty, Population, Dermatology, Hospital Anxiety and Depression Scale, Severity of Illness Index, disease burden, South Africa, 030207 dermatology & venereal diseases, 03 medical and health sciences, Toronto Alexithymia Scale, 0302 clinical medicine, Cost of Illness, Alexithymia, Risk Factors, Psoriasis Area and Severity Index, Internal medicine, Psoriasis, Prevalence, Humans, alexithymia, psoriasis, disease burden, Medicine, Affective Symptoms, Psychiatry, education, Disease burden, Psychiatric Status Rating Scales, education.field_of_study, medicine.diagnostic_test, business.industry, psoriasis, Dermatology Life Quality Index, medicine.disease, 030227 psychiatry, Europe, Case-Control Studies, Quality of Life, Female, alexithymia, business
Abstract

SummaryBackground Single-centre studies show that alexithymia, defined as difficulty in recognizing and describing emotions, is more prevalent among psoriasis patients than in the general population. However, its prevalence and the consequences of the association between alexithymia and psoriasis are unclear. Objectives The primary objective of this study was to determine the prevalence of alexithymia, as defined by a score ≥61 in the 20-item Toronto Alexithymia Scale (TAS-20), in a large sample of patients who had plaque psoriasis for ≤10 years and were eligible for phototherapy or systemic treatment. The secondary objectives were to investigate the relationship between alexithymia and the clinical and psychological aspects of psoriasis. Methods Data were collected in the framework of an observational, multicenter, international study, the EPidemiological Study In Patients With Recently DiagnosEd PSOriasis (EPIDEPSO), aiming at investigating the prevalence of alexithymia and other psychosocial comorbidities in psoriasis patients with ≤10 years disease duration. Results The prevalence of alexithymia within a cohort of 670 patients was 24.8% (95%CI: 21.7-28.2). Patients with alexithymia had a higher burden of psoriasis, including significant impairment of quality of life, higher levels of anxiety and depression, a higher risk of alcohol dependency and impairment of work productivity, compared to patients without alexithymia. Conclusion It is important to identify alexithymic patients with psoriasis in clinical practice as they suffer from a higher disease burden and have a lower ability to express their feelings. This article is protected by copyright. All rights reserved.

Published
2017

32. Web-based teleconsulting in dermatology: a two years pilot experience

Author

Massone, C, Hofmann-Wellenhof, R, Di Stefani, A, Lozzi, Gp, Gabler, G, Dong, H, Argenziano, G, Ozdemir, F, Fink-Puches, R, Salmhofer, W, Zalaudek, I, Soyer, Hp, Massone, C, Hofmann-Wellenhof, R, Di Stefani, A, Lozzi, Gp, Gabler, G, Dong, H, Argenziano, G, Ozdemir, F, Fink-Puches, R, Salmhofer, W, Zalaudek, I, and Soyer, Hp

Published
2006

33. Web-based Teleconsulting in Dermatology: A Two Years Pilot Experience

Author

Massone C, Hofmann-Wellenhof R, Di Stefani A, Lozzi GP, Gabler G, Dong H, Argenziano G, Ozdemir F, Fink-Puches R, Salmhofer W, ZALAUDEK I, Kerl H, Soyer HP., Massone, C, Hofmann-Wellenhof, R, Di Stefani, A, Lozzi, Gp, Gabler, G, Dong, H, Argenziano, G, Özdemir, F, Fink-Puches, R, Salmhofer, W, Zalaudek, I, Kerl, H, Soyer, Hp, Massone C, Ozdemir, F, and Soyer, Hp.

Published
2006

34. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria

Author

Inzinger, M, primary, Wippel-Slupetzky, K, additional, Weger, W, additional, Richter, L, additional, Mlynek, A, additional, Fleischander, B, additional, Scheurecker, C, additional, Sandor, N, additional, Mairhofer, D, additional, Sator, P, additional, Moser-Oberthaler, S, additional, Häring, N, additional, Viznerova, P, additional, Painsi, C, additional, Tanew, A, additional, Ponholzer, P, additional, Tatarski, R, additional, Brenner, W, additional, Stingl, G, additional, Salmhofer, W, additional, Rappersberger, K, additional, Klein, G, additional, Saxinger, W, additional, Auböck, J, additional, Kölli, C, additional, Trautinger, F, additional, Steiner, A, additional, Ratzinger, G, additional, Strohal, R, additional, Riedl, E, additional, Lange-Asschenfeldt, B, additional, Pehamberger, H, additional, Volc-Platzer, B, additional, Selhofer, S, additional, Legat, F, additional, Müllegger, R, additional, Reider, N, additional, Schmuth, M, additional, Hintner, H, additional, Hofer, A, additional, Gruber-Wackernagel, A, additional, Aberer, W, additional, Quehenberger, F, additional, and Wolf, P, additional

Published
2016
Full Text
View/download PDF

35. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate:a randomized clinical trial (TRANSIT)

Author

Adamski, Z, Altomare, G, Aricò, M, Aste, N, Aubin, F, Augustin, M, Ayala, F, Bachelez, H, Baran, E, Barker, J, Belinchón, I, Berbis, P, Bernengo, Mg, Bessis, D, Beylot Barry, M, Bordas Orpinell, Fj, Burden, D, Bylaite, M, Cambazard, F, Carazo, S, Carrascosa, Jm, Carretero, G, Cerio, R, Chimenti, S, David, M, Duval Modeste, Ab, Eedy, D, Estebaranz, L, Filipe, P, Flytström, I, Fonseca, E, Gamanya, R, Ghislain, Pd, Giannetti, A, Girolomoni, G, Gospodinov, D, Griffiths, C, Grob, Jj, Guillet, G, Hernanz Hermosa, Jm, Hoffmann, M, Ioannidis, D, Jacobi, A, Jemec, G, Kadurina, M, Kaszuba, K, Katsambas, A, Kemeny, L, Kerkhof, P, Kragballe, K, Kuzmina, N, Lambert, K, Lázaro, P, Lotti, T, Luger, T, Matz, H, Modiano, P, Moessner, R, Moreno, D, Moreno Jímenez, Jc, Mørk, Nj, Mrowietz, U, Murphy, R, Nicolas, Jf, Nikkels, A, Oliveira, H, Ormerod, A, Ortonne, Jp, Parodi, A, Pasternack, R, Paul, C, Pec, J, PESERICO STECCHINI NEGRI DE SALVI, Andrea, Philipp, S, Piquet, L, Plantin, P, Puig, L, Reich, K, Reményik, E, Riedl, E, Röcken, M, Rustin, M, Saari, S, Saiag, P, Salmhofer, W, Schadendorf, D, Sebastian, M, Simaljakova, M, Simon, Jc, Spirén, A, Stalder, Jf, Stavrianeas, N, Sticherling, M, Ternowitz, T, Thaci, D, Thio, B, Uhlig, D, Valiukeviciene, S, Vanaclocha Sebastián, Fj, and Wozel, G.

Subjects
Male, medicine.medical_specialty, Dermatology, Antibodies, Monoclonal, Humanized, ustekinumab, methotrexate, law.invention, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Psoriasis Area and Severity Index, law, Psoriasis, Internal medicine, Ustekinumab, Clinical endpoint, Medicine, Humans, 030212 general & internal medicine, Dose-Response Relationship, Drug, business.industry, Drug Substitution, digestive, oral, and skin physiology, Dermatology Life Quality Index, psoriasis, Middle Aged, medicine.disease, 3. Good health, Discontinuation, Surgery, Clinical trial, Treatment Outcome, Female, Dermatologic Agents, business, medicine.drug
Abstract

Background: limited data exist on transitioning patients with psoriasis from conventional systemic agents to biologics. Objectives: the TRANSIT study aimed to assess the efficacy and safety of two methotrexate-to-ustekinumab transition strategies. Methods: patients with moderate-to-severe psoriasis and inadequate methotrexate response were randomized 1 : 1 to receive ustekinumab with immediate (arm 1) or 4-week gradual (arm 2) methotrexate withdrawal. Patients weighing ≤ 100 kg or > 100 kg received ustekinumab 45 mg or 90 mg, respectively. The primary endpoint was the frequency of adverse events (AEs) at week 12. Secondary endpoints included additional safety, efficacy and patient-reported outcomes. We report the 12-week efficacy and safety results. Results: overall, 244 patients in arm 1 and 245 in arm 2 were randomized and received ustekinumab. Four patients per arm discontinued the trial by week 12. At week 12 in arms 1 and 2, respectively, 61% and 65% of patients experienced an AE, 2·9% and 2·4% had a serious AE, and 1·2% and 0·4% had an AE leading to ustekinumab discontinuation. In arms 1 and 2, respectively, median Psoriasis Area and Severity Index (PASI) score decreased from 15·2 and 15·4 at baseline to 2·9 and 2·8 at week 12; 58% and 62% of patients achieved a 75% reduction from baseline in PASI score (PASI 75) at week 12; median baseline Dermatology Life Quality Index fell from 8 and 9 at baseline to 1 (both arms) at week 16. Conclusions: ustekinumab was well tolerated and effective in patients who had an inadequate response to methotrexate. Both transition strategies resulted in similar week 12 safety and efficacy outcomes.

Published
2013

36. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis

Author

Adamski, Z, Altomare, G, Aricò, M, Aste, N, Aubin, F, Augustin, M, Ayala, F, Bachelez, H, Baran, E, Barker, J, Belinchón, I, Berbis, P, Bernengo, Mg, Bessis, D, Beylot Barry, M, Bordas Orpinell, Fj, Burden, D, Bylaite, M, Cambazard, F, Carazo, S, Carrascosa, Jm, Carretero, G, Cerio, R, Chimenti, S, David, M, Duval Modeste, Ab, Eedy, D, Estebaranz, L, Filipe, P, Flytström, I, Fonseca, E, Gamanya, R, Ghislain, Pd, Giannetti, A, Girolomoni, G, Gospodinov, D, Griffiths, C, Grob, Jj, Guillet, G, Hernanz Hermosa, Jm, Hoffmann, M, Ioannidis, D, Jacobi, A, Jemec, G, Kadurina, M, Kaszuba, K, Katsambas, A, Kemeny, L, Kerkhof, P, Kragballe, K, Kuzmina, N, Lambert, K, Lázaro, P, Lotti, T, Luger, T, Matz, H, Modiano, P, Moessner, R, Moreno, D, Moreno Jímenez, Jc, Mørk, Nj, Mrowietz, U, Murphy, R, Nicolas, Jf, Nikkels, A, Oliveira, H, Ormerod, A, Ortonne, Jp, Parodi, A, Pasternack, R, Paul, C, Pec, J, PESERICO STECCHINI NEGRI DE SALVI, Andrea, Philipp, S, Piquet, L, Plantin, P, Puig, L, Reich, K, Reményik, E, Riedl, E, Röcken, M, Rustin, M, Saari, S, Saiag, P, Salmhofer, W, Schadendorf, D, Sebastian, M, Simaljakova, M, Simon, Jc, Spirén, A, Stalder, Jf, Stavrianeas, N, Sticherling, M, Ternowitz, T, Thaci, D, Thio, B, Uhlig, D, Valiukeviciene, S, Vanaclocha Sebastián, Fj, and Wozel, G.

Subjects
Male, medicine.medical_specialty, Population, Dermatology, Antibodies, Monoclonal, Humanized, law.invention, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Psoriasis Area and Severity Index, Internal medicine, Psoriasis, Ustekinumab, Clinical endpoint, medicine, Humans, 030212 general & internal medicine, Adverse effect, education, education.field_of_study, Dose-Response Relationship, Drug, business.industry, Drug Substitution, Middle Aged, medicine.disease, 3. Good health, Surgery, Regimen, Methotrexate, Treatment Outcome, Female, Dermatologic Agents, business, psoriasis, ustekinumab, methotrexate, medicine.drug
Abstract

Background: There are limited long-term, ‘real-world’ data on ustekinumab, or the effect of dose adjustment in suboptimal responders. Objectives: We describe 52-week data from TRANSIT, which initiated ustekinumab by licensed regimen and investigated exploratory dose adjustment. Methods: Patients with moderate-to-severe psoriasis and inadequate methotrexate response received ustekinumab, with immediate or gradual methotrexate withdrawal. Outcomes were similar between treatment arms at week 12 (primary endpoint), so week 52 data were pooled. Patients weighing ≤ 100 kg or > 100 kg were administered ustekinumab 45 or 90 mg, respectively. Patients weighing ≤ 100 kg without 75% improvement in Psoriasis Area and Severity Index (PASI 75) response at weeks 28 or 40 received a dose adjustment to 90 mg. The primary analysis used observed data. Results: Overall, 391 and 98 patients received ustekinumab 45 and 90 mg, respectively. Forty-four patients (9%) discontinued before week 52 (0·4% due to adverse events). At week 52 (in the overall population), 369 patients (83%) achieved a PASI score ≤ 5, and 341 patients (77%) achieved PASI 75; the median PASI score decreased from 15 at baseline to 1·8. At weeks 28 and 40, 84 and 31 patients, respectively, did not achieve PASI 75 and received a dose adjustment; by week 52, 35/82 (43%) and 15/31 (48%) of these patients, respectively, achieved PASI 75 (two discontinued between weeks 28 and 40). Conclusions: Ustekinumab showed sustained 1-year efficacy and was well tolerated when initially administered according to label. Adjusting the ustekinumab dose to 90 mg may result in clinically meaningful improvement in response in patients weighing ≤ 100 kg with suboptimal initial response.

Published
2013

38. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.

Author

Strange, A., Capon, F., Spencer, C.C., Knight, J., Weale, M.E., Allen, M.H., Barton, A., Band, G., Bellenguez, C., Bergboer, J.G.M., Blackwell, J.M., Bramon, E., Bumpstead, S.J., Casas, J.P., Cork, M.J., Corvin, A., Deloukas, P., Dilthey, A., Duncanson, A., Edkins, S., Estivill, X., Fitzgerald, O., Freeman, C., Giardina, E., Gray, E., Hofer, A., Huffmeier, U., Hunt, S.E., Irvine, A.D., Jankowski, J., Kirby, B., Langford, C., Lascorz, J., Leman, J., Leslie, S., Mallbris, L., Markus, H.S., Mathew, C.G., McLean, W.H.I., McManus, R., Mossner, R., Moutsianas, L., Naluai, A.T., Nestle, F.O., Novelli, G., Onoufriadis, A., Palmer, C.N., Perricone, C., Pirinen, M., Plomin, R., Potter, S.C., Pujol, R.M., Rautanen, A., Riveira-Munoz, E., Ryan, A.W., Salmhofer, W., Samuelsson, L., Sawcer, S.J., Schalkwijk, J., Smith, C.H., Stahle, M., Su, Z., Tazi-Ahnini, R., Traupe, H., Viswanathan, A.C., Warren, R.B., Weger, W., Wolk, K., Wood, N., Worthington, J., Young, H.S., Zeeuwen, P.L.J.M., Hayday, A., Burden, A.D., Griffiths, C.E., Kere, J., Reis, A., McVean, G., Evans, D.M., Brown, M.A., Barker, J.N., Peltonen, L., Donnelly, P., Trembath, R.C., Strange, A., Capon, F., Spencer, C.C., Knight, J., Weale, M.E., Allen, M.H., Barton, A., Band, G., Bellenguez, C., Bergboer, J.G.M., Blackwell, J.M., Bramon, E., Bumpstead, S.J., Casas, J.P., Cork, M.J., Corvin, A., Deloukas, P., Dilthey, A., Duncanson, A., Edkins, S., Estivill, X., Fitzgerald, O., Freeman, C., Giardina, E., Gray, E., Hofer, A., Huffmeier, U., Hunt, S.E., Irvine, A.D., Jankowski, J., Kirby, B., Langford, C., Lascorz, J., Leman, J., Leslie, S., Mallbris, L., Markus, H.S., Mathew, C.G., McLean, W.H.I., McManus, R., Mossner, R., Moutsianas, L., Naluai, A.T., Nestle, F.O., Novelli, G., Onoufriadis, A., Palmer, C.N., Perricone, C., Pirinen, M., Plomin, R., Potter, S.C., Pujol, R.M., Rautanen, A., Riveira-Munoz, E., Ryan, A.W., Salmhofer, W., Samuelsson, L., Sawcer, S.J., Schalkwijk, J., Smith, C.H., Stahle, M., Su, Z., Tazi-Ahnini, R., Traupe, H., Viswanathan, A.C., Warren, R.B., Weger, W., Wolk, K., Wood, N., Worthington, J., Young, H.S., Zeeuwen, P.L.J.M., Hayday, A., Burden, A.D., Griffiths, C.E., Kere, J., Reis, A., McVean, G., Evans, D.M., Brown, M.A., Barker, J.N., Peltonen, L., Donnelly, P., and Trembath, R.C.

Abstract

1 november 2010, Contains fulltext : 89179.pdf (publisher's version ) (Closed access), To identify new susceptibility loci for psoriasis, we undertook a genome-wide association study of 594,224 SNPs in 2,622 individuals with psoriasis and 5,667 controls. We identified associations at eight previously unreported genomic loci. Seven loci harbored genes with recognized immune functions (IL28RA, REL, IFIH1, ERAP1, TRAF3IP2, NFKBIA and TYK2). These associations were replicated in 9,079 European samples (six loci with a combined P < 5 x 10 and two loci with a combined P < 5 x 10). We also report compelling evidence for an interaction between the HLA-C and ERAP1 loci (combined P = 6.95 x 10). ERAP1 plays an important role in MHC class I peptide processing. ERAP1 variants only influenced psoriasis susceptibility in individuals carrying the HLA-C risk allele. Our findings implicate pathways that integrate epidermal barrier dysfunction with innate and adaptive immune dysregulation in psoriasis pathogenesis.

Published
2010

46. Novel mutations in the HSN2 gene causing hereditary sensory and autonomic neuropathy type II

Author

Coen, K., primary, Pareyson, D., additional, Auer-Grumbach, M., additional, Buyse, G., additional, Goemans, N., additional, Claeys, K. G., additional, Verpoorten, N., additional, Laura, M., additional, Scaioli, V., additional, Salmhofer, W., additional, Pieber, T. R., additional, Nelis, E., additional, De Jonghe, P., additional, and Timmerman, V., additional

Published
2006
Full Text
View/download PDF

47. Two years' experience with Web-based teleconsulting in dermatology

Author

Massone, C, primary, Soyer, H P, additional, Hofmann-Wellenhof, R, additional, Di Stefani, A, additional, Lozzi, G P, additional, Gabler, G, additional, Dong, H, additional, Argenziano, G, additional, Ozdemir, F, additional, Fink-Puches, R, additional, Salmhofer, W, additional, Zalaudek, I, additional, Nunzi, E, additional, and Kerl, H, additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results